Tags

Type your tag names separated by a space and hit enter

Intraductal carcinoma of the prostate: precursor or aggressive phenotype of prostate cancer?
Prostate. 2013 Mar; 73(4):442-8.P

Abstract

BACKGROUND

Although the term "intraductal carcinoma of the prostate" (IDC-P) was introduced almost 40 years ago, there is still the lack of appreciation that this entity represents a clinically aggressive disease that continues to be misreported under the diagnostic category of high grade prostatic intraepithelial neoplasia (HGPIN).

METHODS

Recent data obtained from histological, molecular, and clinical studies were reviewed to demonstrate that IDC-P significantly differs from HGPIN, and has a major impact in terms of diagnosis, prognosis and therapy of prostate cancer (PCa).

RESULTS

HGPIN is the only accepted precursor of PCa. Its diagnosis in prostate biopsies has no prognostic implications, and does not dictate therapeutic decisions. By contrast, IDC-P correlates with a worse pathological and clinical outcome. IDC-P differs from HGPIN by distinct histological and molecular features. Recent clinical studies report that IDC-P is associated with neoadjuvant androgen deprivation therapy (ADT) and, chemotherapy (CT) failure as well as early disease recurrence after external beam radiation. Finally, IDC-P is associated with TMPRSS2-ERG gene fusion, which was reported to be regulated by estrogens and their receptors.

CONCLUSIONS

IDC-P is an aggressive phenotype of prostate cancer and predicts poor response to ADT, CT, and external beam radiation. IDC-P should be separated from HGPIN and should be reported in prostate biopsies and prostatectomy specimens.

Links

Aggregator Full Text

Authors+Show Affiliations

Bonkhoff H
Pathology Laboratory, Berlin, Germany. info@prostapath.de
Wheeler TM
No affiliation info available
van der Kwast TH
No affiliation info available
Magi-Galluzzi C
No affiliation info available
Montironi R
No affiliation info available
Cohen RJ
No affiliation info available

MeSH

AnimalsCarcinoma, DuctalHumansMaleNeoplasm InvasivenessPhenotypeProstatic Neoplasms

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

22949099

Citation

Bonkhoff, Helmut, et al. "Intraductal Carcinoma of the Prostate: Precursor or Aggressive Phenotype of Prostate Cancer?" The Prostate, vol. 73, no. 4, 2013, pp. 442-8.
Bonkhoff H, Wheeler TM, van der Kwast TH, et al. Intraductal carcinoma of the prostate: precursor or aggressive phenotype of prostate cancer? Prostate. 2013;73(4):442-8.
Bonkhoff, H., Wheeler, T. M., van der Kwast, T. H., Magi-Galluzzi, C., Montironi, R., & Cohen, R. J. (2013). Intraductal carcinoma of the prostate: precursor or aggressive phenotype of prostate cancer? The Prostate, 73(4), 442-8. https://doi.org/10.1002/pros.22579
Bonkhoff H, et al. Intraductal Carcinoma of the Prostate: Precursor or Aggressive Phenotype of Prostate Cancer. Prostate. 2013;73(4):442-8. PubMed PMID: 22949099.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Intraductal carcinoma of the prostate: precursor or aggressive phenotype of prostate cancer? AU - Bonkhoff,Helmut, AU - Wheeler,Thomas M, AU - van der Kwast,Theodorus H, AU - Magi-Galluzzi,Cristina, AU - Montironi,Rodolfo, AU - Cohen,Ronald J, Y1 - 2012/09/04/ PY - 2012/06/19/received PY - 2012/08/06/accepted PY - 2012/9/6/entrez PY - 2012/9/6/pubmed PY - 2013/3/26/medline SP - 442 EP - 8 JF - The Prostate JO - Prostate VL - 73 IS - 4 N2 - BACKGROUND: Although the term "intraductal carcinoma of the prostate" (IDC-P) was introduced almost 40 years ago, there is still the lack of appreciation that this entity represents a clinically aggressive disease that continues to be misreported under the diagnostic category of high grade prostatic intraepithelial neoplasia (HGPIN). METHODS: Recent data obtained from histological, molecular, and clinical studies were reviewed to demonstrate that IDC-P significantly differs from HGPIN, and has a major impact in terms of diagnosis, prognosis and therapy of prostate cancer (PCa). RESULTS: HGPIN is the only accepted precursor of PCa. Its diagnosis in prostate biopsies has no prognostic implications, and does not dictate therapeutic decisions. By contrast, IDC-P correlates with a worse pathological and clinical outcome. IDC-P differs from HGPIN by distinct histological and molecular features. Recent clinical studies report that IDC-P is associated with neoadjuvant androgen deprivation therapy (ADT) and, chemotherapy (CT) failure as well as early disease recurrence after external beam radiation. Finally, IDC-P is associated with TMPRSS2-ERG gene fusion, which was reported to be regulated by estrogens and their receptors. CONCLUSIONS: IDC-P is an aggressive phenotype of prostate cancer and predicts poor response to ADT, CT, and external beam radiation. IDC-P should be separated from HGPIN and should be reported in prostate biopsies and prostatectomy specimens. SN - 1097-0045 UR - https://www.unboundmedicine.com/medline/citation/22949099/Intraductal_carcinoma_of_the_prostate:_precursor_or_aggressive_phenotype_of_prostate_cancer L2 - https://doi.org/10.1002/pros.22579 DB - PRIME DP - Unbound Medicine ER -